Overview
Aptos (APT) and Injective (INJ) sit at different layers of the crypto stack. At current prices ($0.563000 vs $5.07), market leadership still favors Aptos on capitalization, while 24h tape is led by Injective.
Quick winners
Full comparison
| Metric | APT | INJ |
|---|---|---|
| Price | $0.563000 | $5.07 |
| Market Cap | $529.32M | $490.41M |
| FDV | — | — |
| Volume 24h | $2.28M | $2.62M |
| Circulating Supply | — | — |
| Total Supply | — | — |
| Max Supply | — | — |
| Rank | 102.00 | 99.00 |
| Dominance | — | — |
| Liquidity | — | — |
| Volatility | +5.13% | +5.78% |
| ATH | — | — |
| ATL | — | — |
| ROI | — | — |
Performance
| Timeframe | APT | INJ |
|---|---|---|
| 1H | — | — |
| 24H | +2.18% | +3.42% |
| 7D | — | — |
| 30D | — | — |
| 90D | — | — |
| 1Y | — | — |
| YTD | — | — |
| ALL | — | — |
Comparative chart
Technical indicators
| Indicator | APT | INJ |
|---|---|---|
| RSI | 40.11 | 53.92 |
| MACD histogram | — | — |
| EMA20 | — | — |
| EMA50 | — | — |
| EMA100 | — | — |
| EMA200 | — | — |
| SMA50 | — | — |
| SMA200 | — | — |
| ATR | 0.03 | 0.29 |
| ADX | 28.30 | 12.69 |
| Support | — | 4.91 |
| Resistance | 0.64 | 5.47 |
| Trend | bearish | neutral |
| Momentum | — | — |
| Signal | neutral | neutral |
Automatic technical analysis
Technically, Aptos shows RSI 40.11 with trend bias bearish, while Injective sits at RSI 53.92 (neutral). Divergences between momentum and price should be confirmed on higher timeframes.
Fundamentals
| Metric | APT | INJ |
|---|---|---|
| Consensus | — | — |
| Blockchain | — | — |
| TPS | — | — |
| Block time | — | — |
| Finality | — | — |
| Validators | — | — |
| Staking | — | — |
| TVL | — | — |
| Supply model | — | — |
| Inflation | — | — |
| Developer activity | 0.00 | 0.00 |
| Github activity | 0.00 | 118.00 |
| On-chain activity | — | — |
| Whale activity | — | — |
| Addresses | — | — |
| Gas fees | — | — |
Ecosystem
Aptos
Injective
Pros and cons
Pros of Aptos
- Aptos typically benefits from deeper liquidity and broader market recognition inside the Top 300 set.
- APT often anchors narratives that attract sustained media and analyst coverage.
- Higher ranking for Aptos can translate into tighter spreads on major venues.
Cons of Aptos
- Data gaps in niche fundamentals still apply — absence of a field is not confirmation.
- Regulatory or macro headlines can hit Aptos harder simply because it is more visible.
- Crowded positioning around APT sometimes amplifies squeeze or flush risk.
Pros of Injective
- Injective can offer higher relative beta when market attention rotates toward its niche.
- PEPS tracking for Injective still includes AI score and level context for monitoring.
- Diversifying versus Aptos with Injective can change portfolio factor exposure.
- If technical momentum aligns, Injective may outperform on medium-term windows.
Cons of Injective
- Relative underperformance versus Aptos can persist through entire market regimes.
- Higher volatility on INJ cuts both ways and demands stricter risk limits.
- Smaller book depth versus large caps can increase slippage for Injective.
- Incomplete fundamental coverage can hide operational or tokenomic risks.
Which looks stronger right now?
On the latest snapshot, market-cap leadership belongs to Aptos, while short-term performance leans toward Injective. That mix suggests relative strength can flip quickly, so size risk accordingly.
AI summary
This AI-assisted summary starts from live PEPS fields. Aptos holds market-cap $529.32M and rank #102; Injective shows $490.41M and #99. Where liquidity and flow matter, watch Injective. Where durability matters, watch Aptos. AI composite scores (48.00/48.80) compress those tensions into a single lens. In probabilistic terms, the side winning more columns may have a nearer-term edge, but tails remain fat. Revisit after the next hourly refresh.
FAQ
Which is better, Aptos or Injective?
“Better” depends on horizon and risk. Aptos leads on market cap today, while Injective leads the 24h move — neither is a guarantee.
Which has more upside potential, APT or INJ?
Higher-beta assets can move more in both directions. Use performance tables and volatility, not headlines, to judge potential ranges.
Which is less risky right now?
Lower volatility and deeper liquidity usually imply milder path risk, but crypto tails remain large for both Aptos and Injective.
Which has stronger developer activity?
Check the fundamentals table for developer/github fields when populated. Missing values mean the feed has no reliable reading yet.
Which looks more decentralized?
Decentralization is multi-dimensional (validators, client diversity, token distribution). This page surfaces available consensus/validator fields without over-claiming.
Which has lower fees?
Fee comparisons belong to each network’s fee market. Where gas/fee metrics exist in fundamentals, compare them; otherwise verify on explorers.
Which is better for investing?
Investing choices need personal constraints. Use this comparison as research input, then size positions with an explicit invalidation plan.
Which is better for staking?
If staking fields are present, compare yield mechanics and lockups off-platform. Staking returns are not risk-free.
Which is more used day to day?
Volume, on-chain activity and ecosystem links are practical usage proxies. Injective currently leads traded volume on this snapshot.
Which has the better recent performance?
See the performance table across 1h through 1y. The 24h leader is Injective, but longer windows can disagree.